Cellmid Ltd (CDY)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Cellmid Ltd (CDY) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011318
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd is a developer of therapies and diagnostic tests. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair loss products and evolis products. Cellmid is developing three therapeutic programs including AB102 oncology antibody, CAB101 inflammation antibody, and CMK103 cardiac ischemia. The company’s products are used for the treatment and detection of cancers, the treatment of inflammatory, autoimmune diseases, and ischemic heart disease. It markets its products in Australia and Japan. Cellmid is headquartered in Sydney, New South Wales, Australia.

Cellmid Ltd (CDY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cellmid Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Cellmid Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Cellmid Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Cellmid Ltd, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Cellmid Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Cellmid Ltd, Medical Equipment, Deal Details 10
Partnerships 10
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 10
Equity Offering 11
Cellmid to Raise USD0.8 Million in Private Placement of Shares 11
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 12
Cellmid Completes Private Placement Of Shares For US$1.8 Million 13
Cellmid Completes Private Placement Of Shares For US$2 Million 14
Cellmid Completes Private Placement Of Shares For US$0.3 Million 15
Cellmid Ltd – Key Competitors 16
Cellmid Ltd – Key Employees 17
Cellmid Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Apr 08, 2016: Cellmid: Midkine Strategy Update 19
Financial Announcements 20
Sep 27, 2017: Cellmid’s FY2017 Results Presentation 20
Feb 25, 2016: Interim Financial Report For the Half-Year Ended 31 December 2015 : Cellmid 21
Corporate Communications 24
Oct 16, 2017: Cellmid Appoints Dr Martin Cross as Non-executive Director 24
May 09, 2016: Significant Scientific Appointment for Cellmid Advisory Board Chair 25
Other Significant Developments 26
Oct 25, 2017: Cellmid: Notes to the Appendix 4C 26
May 26, 2016: Cellmid provides update on Japanese sale 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Cellmid Ltd, Medical Equipment, Key Facts, 2017 2
Cellmid Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Cellmid Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Cellmid Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Cellmid Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Cellmid Ltd, Deals By Market, 2011 to YTD 2017 8
Cellmid Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 10
Cellmid to Raise USD0.8 Million in Private Placement of Shares 11
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 12
Cellmid Completes Private Placement Of Shares For US$1.8 Million 13
Cellmid Completes Private Placement Of Shares For US$2 Million 14
Cellmid Completes Private Placement Of Shares For US$0.3 Million 15
Cellmid Ltd, Key Competitors 16
Cellmid Ltd, Key Employees 17
Cellmid Ltd, Subsidiaries 18

★海外企業調査レポート[Cellmid Ltd (CDY)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Avantium NV (AVTX):企業の財務・戦略的SWOT分析
    Avantium NV (AVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Albireo Pharma Inc (ALBO):医療機器:M&Aディール及び事業提携情報
    Summary Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe med …
  • Autoliv, Inc.:企業の戦略・SWOT・財務分析
    Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report Summary Autoliv, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • PolyNovo Ltd (PNV)-医療機器分野:企業M&A・提携分析
    Summary PolyNovo Ltd (PolyNovo), formerly Calzada Ltd is a medical device company that develops, manufactures and commercializes biodegradable polymers for use in medical devices. The company offers products such as biodegradable temporizing matrix and negative pressure wound therapy dressing system …
  • Arab International Bank
    Arab International Bank - Strategy, SWOT and Corporate Finance Report Summary Arab International Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Pfizer Ltd India (PFIZER):企業の財務・戦略的SWOT分析
    Summary Pfizer Ltd India (Pfizer India) a subsidiary of Pfizer Inc, operates as a pharmaceutical company that develops medicines for brain disorders. The company’s products portfolio comprises of anti-allergics, anti-diabetics, anti-histamines, anti-infectives, anti-parasitics, drugs for cardiovascu …
  • Global Sweeteners Holdings Limited (3889):企業の財務・戦略的SWOT分析
    Global Sweeteners Holdings Limited (3889) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • MeiraGTx Holdings Plc (MGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary MeiraGTx Holdings Plc (MeiraGTx) is an independent clinical-stage gene therapy company that focuses on the development of therapeutics for the treatment of eye, salivary gland and neurodegenerative diseases. The company’s pipeline of preclinical and research programs include AAV-CNGB3, for a …
  • Stemline Therapeutics Inc (STML):企業の財務・戦略的SWOT分析
    Summary Stemline Therapeutics Inc (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pi …
  • Consumers Energy Co (CMS PR B):石油・ガス:M&Aディール及び事業提携情報
    Summary Consumers Energy Co (Consumers), formerly Consumers Power, is an electric and natural gas utility. The company generates purchases, transmits, distributes, and sells electricity. It also carries out the purchase, transmission, storage, distribution, and sale of natural gas. It generates elec …
  • Avalon Oil & Gas Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Avalon Oil & Gas Inc (Avalon), formerly Snow Runner (USA) Inc is an oil and gas company that develops and operates crude oil and natural gas properties. The company acquires, produces and develops oil and natural gas reserves. It offers reservoir maintenance and technologies to produce portf …
  • Iamgold Corporation:企業の戦略・SWOT・財務情報
    Iamgold Corporation - Strategy, SWOT and Corporate Finance Report Summary Iamgold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Electricity & Water Authority:企業の戦略的SWOT分析
    Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • McConnell Dowell Corp Ltd:企業の戦略的SWOT分析
    McConnell Dowell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Somnomed Ltd (SOM):企業の財務・戦略的SWOT分析
    Summary Somnomed Ltd (SomnoMed) is a medical device company that develops, produces, commercializes and markets devices for the oral treatment of sleep-related disorders. The company’s products include Somnodent, an oral appliance for obstructive sleep apnea; and Somnobrux, a mouthguard that protect …
  • EnerSys (ENS):企業の財務・戦略的SWOT分析
    EnerSys (ENS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Tetra Tech. Inc:企業のM&A・事業提携・投資動向
    Tetra Tech. Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tetra Tech. Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Ryanair Holdings plc:戦略・SWOT・企業財務分析
    Ryanair Holdings plc - Strategy, SWOT and Corporate Finance Report Summary Ryanair Holdings plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kaneka Corp (4118):医療機器:M&Aディール及び事業提携情報
    Summary Kaneka Corp (Kaneka) is a chemical manufacturing company. Its product offerings include polyvinyl chloride, caustic soda, hydrochloric acid, flexible PVC compounds, rigid PVC compounds, paste PVC and chlorinated PVC. Its products include functional plastics, expandable plastics and products, …
  • Baytex Energy Corp (BTE):企業の財務・戦略的SWOT分析
    Baytex Energy Corp (BTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆